Kite lines up a JV in Chi­na while Dai­ichi Sankyo strikes $250M-plus deal to launch CAR-T drug in Japan

With its new drug ap­pli­ca­tion for the pi­o­neer­ing CAR-T drug KTE-C19 in the fi­nal weeks from be­ing com­plet­ed and shipped to reg­u­la­tors in search of an ac­cel­er­at­ed ap­proval, Kite Phar­ma $KITE has now lined up two part­ners to man­age their prospec­tive leap in­to two key Asian mar­kets. Kite has pulled the wraps off a joint ven­ture for Chi­na while ink­ing a $250 mil­lion-plus deal to break in­to the Japan­ese mar­ket along­side Dai­ichi Sankyo.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.